OPNT: Acquires Drinabant for Acute Cannabinoid Overdose…

By David Bautz, PhD

NASDAQ:OPNT

READ THE FULL OPNT RESEARCH REPORT

Business Update

Acquires Drinabant for Acute Cannabinoid Overdose

On December 26, 2018, Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) announced the acquisition of drinabant, a novel CB-1 receptor antagonist, for the treatment of acute cannabinoid overdose (ACO). Opiant will pay Sanofi an upfront payment of $500,000 and will be responsible for all development and commercialization activities.

ACO in adults, which typically occurs from the ingestion of marijuana edibles or the use of synthetic cannabinoids, can result in anxiety, nausea, agitation, and hallucinations. In children, in which the cause is almost always

...read more at https://scr.zacks.com/News/Press-Releases/Press-Release-Details/2019/OPNT-Acquires-Drinabant-for-Acute-Cannabinoid-Overdose-article/default.aspx

by

Leave a Reply